This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells
Scientific Reports Open Access 26 February 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kling, J. PARP inhibitors blaze a trail in difficult-to-treat cancers. Nat Biotechnol 27, 784–785 (2009). https://doi.org/10.1038/nbt0909-784
Issue Date:
DOI: https://doi.org/10.1038/nbt0909-784
This article is cited by
-
Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells
Scientific Reports (2016)
-
PARP inhibitors stumble in breast cancer
Nature Biotechnology (2011)
-
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Breast Cancer Research (2009)